Cytosorbents Corp CTSO
Medical/Dental Instruments · data as of November 13, 2026
Cytosorbents Corp (CTSO) is a healthcare company listed in the US with a market value of about $15M. In the twelve months to June 30, 2026 it had revenue of $37M and net income of -$18M, a net margin of -48.9%.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -48%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.
About Cytosorbents
Cytosorbents is listed in the US and classified in medical/dental instruments. Revenue went from $41M in 2020 to $37M in 2025, a decline of about 2.0% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 43% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- Profit margin improving
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $37M | $37M | $36M | $31M | $35M | $43M | $41M |
| Net income | -$18M | -$8M | -$21M | -$29M | -$33M | -$25M | -$8M |
| Free cash flow | -$9M | -$13M | -$15M | -$22M | -$34M | -$18M | -$6M |
| EPS (diluted) | $-5.80 | $-2.60 | $-7.60 | $-13.00 | $-15.00 | $-11.40 | $-4.00 |
| Net margin | -48.9% | -22.1% | -58.2% | -94.1% | -94.6% | -56.9% | -19.1% |
| ROIC | — | -40.2% | -40.0% | -74.4% | -56.9% | -28.9% | -11.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $47.50, 875% above the current price; targets range from $15.00 to $80.00; the consensus rating is “none”; expected EPS is $-4.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Cytosorbents stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cytosorbents pay a dividend?
Not currently.
Is Cytosorbents a good stock to buy?
We do not give buy or sell advice. Cytosorbents scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.